A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia

被引：1

作者：

Short, Nicholas J. ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Alvarado, Yesid ^{[1
]}

Burger, Jan A. ^{[1
]}

Jain, Nitin ^{[1
]}

Konopleva, Marina ^{[1
]}

Ravandi, Farhad ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Masarova, Lucia ^{[1
]}

Sasaki, Koji ^{[1
]}

Thompson, Philip A. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Jacob, Jovitta ^{[1
]}

Milton, Anna ^{[1
]}

Garris, Rebecca ^{[1
]}

Jabbour, Elias J. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-154124

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2299

引用

页数：6

共 50 条

[21] Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Richard-Carpentier, Guillaume
Kantarjian, Hagop M.
Jorgensen, Jeffrey L.
Wang, Sa A.
Khoury, Joseph D.
Ravandi, Farhad
Short, Nicholas J.
Khouri, Rita
Takahashi, Koichi
Ohanian, Maro
Borthakur, Gautam M.
Konopleva, Marina Y.
Daver, Naval G.
Estrov, Zeev E.
Alvarado, Yesid
Jain, Nitin
Kadia, Tapan M.
Garcia-Manero, Guillermo
Velasquez, Michelle
Nasnas, Patrice
O'Brien, Susan
Jabbour, Elias
BLOOD, 2019, 134
[22] Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Jain, Nitin
Maiti, Abhishek
Ravandi, Farhad
Konopleva, Marina
Daver, Naval
Kadia, Tapan
Pemmaraju, Naveen
Short, Nicholas
Kebriaei, Partow
Ning, Jing
Cortes, Jorge
Jabbour, Elias
Kantarjian, Hagop
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : 1000 - 1007
[23] Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
Abou Dalle, Iman
Jabbour, Elias
Short, Nicholas J.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[24] Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Hein, Kyaw
Short, Nicholas
Jabbour, Elias
Yilmaz, Musa
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 7 - 16
[25] A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
Brivio, Erica
Locatelli, Franco
Lopez-Yurda, Marta
Malone, Andrea
Diaz-de-Heredia, Cristina
Bielorai, Bella
Rossig, Claudia
van der Velden, Vincent H. J.
Ammerlaan, Anneke C. J.
Thano, Adriana
van der Sluis, Inge M.
den Boer, Monique L.
Chen, Ying
Sleight, Barbara
Brethon, Benoit
Nysom, Karsten
Sramkova, Lucie
Ora, Ingrid
Vinti, Luciana
Chen-Santel, Christiane
Zwaan, Christian Michel
BLOOD, 2021, 137 (12) : 1582 - 1590
[26] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Irina Proskorovsky
Yun Su
Kyle Fahrbach
Erik Vandendries
Véronique Pagé
Uchenna Onyekwere
Yunyang Wang
Joseph C. Cappelleri
Matthias Stelljes
Advances in Therapy, 2019, 36 : 2147 - 2160
[27] Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia
Stock, Wendy
Martinelli, Giovanni
Stelljes, Matthias
DeAngelo, Daniel J.
Goekbuget, Nicola
Advani, Anjali S.
O'Brien, Susan
Liedtke, Michaela
Merchant, Akil A.
Cassaday, Ryan D.
Wang, Tao
Zhang, Hui
Vandendries, Erik
Jabbour, Elias
Marks, David, I
Kantarjian, Hagop M.
CANCER, 2021, 127 (06) : 905 - 913
[28] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
Proskorovsky, Irina
Su, Yun
Fahrbach, Kyle
Vandendries, Erik
Page, Veronique
Onyekwere, Uchenna
Wang, Yunyang
Cappelleri, Joseph C.
Stelljes, Matthias
ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
[29] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Pennesi, Edoardo
Michels, Naomi
Brivio, Erica
van der Velden, Vincent H. J.
Jiang, Yilin
Thano, Adriana
Ammerlaan, Anneke J. C.
Boer, Judith M.
Beverloo, H. Berna
Sleight, Barbara
Chen, Ying
Vormoor-Buerger, Britta
Rives, Susana
Bielorai, Bella
Roessig, Claudia
Petit, Arnaud
Rizzari, Carmelo
Engstler, Gernot
Stary, Jan
Bautista Sirvent, Francisco J.
Chen-Santel, Christiane
Bruno, Benedicte
Bertrand, Yves
Rialland, Fanny
Plat, Genevieve
Reinhardt, Dirk
Vinti, Luciana
Von Stackelberg, Arend
Locatelli, Franco
Zwaan, Christian M.
LEUKEMIA, 2022, 36 (06) : 1516 - 1524
[30] Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Edoardo Pennesi
Naomi Michels
Erica Brivio
Vincent H. J. van der Velden
Yilin Jiang
Adriana Thano
Anneke J. C. Ammerlaan
Judith M. Boer
H. Berna Beverloo
Barbara Sleight
Ying Chen
Britta Vormoor-Bürger
Susana Rives
Bella Bielorai
Claudia Rössig
Arnaud Petit
Carmelo Rizzari
Gernot Engstler
Jan Starý
Francisco J. Bautista Sirvent
Christiane Chen-Santel
Benedicte Bruno
Yves Bertrand
Fanny Rialland
Geneviève Plat
Dirk Reinhardt
Luciana Vinti
Arend Von Stackelberg
Franco Locatelli
Christian M. Zwaan
Leukemia, 2022, 36 : 1516 - 1524

← 1 2 3 4 5 →